KLP Kapitalforvaltning AS Has $25.18 Million Position in Edwards Lifesciences Corporation $EW

KLP Kapitalforvaltning AS cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 295,322 shares of the medical research company’s stock after selling 10,900 shares during the quarter. KLP Kapitalforvaltning AS owned 0.05% of Edwards Lifesciences worth $25,176,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in EW. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. True Wealth Design LLC raised its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares in the last quarter. Rakuten Securities Inc. increased its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Hantz Financial Services Inc. increased its position in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. Finally, Dorato Capital Management acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 2.2%

EW opened at $81.47 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $69.84 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $46.97 billion, a price-to-earnings ratio of 44.52, a PEG ratio of 2.08 and a beta of 0.95. The company’s 50 day moving average price is $81.47 and its two-hundred day moving average price is $82.17.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. The company’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.96 earnings per share for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. This represents a 51.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 86,058 shares of company stock valued at $7,118,636. 0.31% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on EW shares. Evercore reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, BTIG Research reiterated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $95.74.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.